1 BTC
=
- USD
LENZ Therapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About LENZ Therapeutics, Inc. Common Stock
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Market Statistics
Trading Metrics
How to Buy LENZ
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy LENZ
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesThe presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, including Phentolamine, MicroLine, GLK-302, and CorVision, alongside already-approved treatments like VUITY, QLOSI, VIZZ, and YUVEZZI.
Lenz Therapeutics stock plummeted 11.2% after missing Q4 earnings and sales expectations. The vision drug company reported a loss of $1.16 per share on $1.6 million in sales, versus analyst forecasts of $0.90 loss on $3.1 million in sales. Despite being on pace for 45,000 VIZZ prescriptions by end of Q1 2026, weak launch quarter uptake and quadrupled SG&A expenses disappointed investors. Management's lack of forward guidance further fueled the selloff.
Lenz Therapeutics reported $5.0 million in Q2 2025 revenue from licensing deals, exceeding analyst expectations. The company is preparing for FDA review of LNZ100, an eye drop for presbyopia, with a decision expected by August 8, 2025. Despite increased operating expenses leading to a wider net loss, Lenz remains focused on commercial readiness.
Capstone data from Phase 3 CLARITY study to be presented
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that Eef Schimmelpennink, President and Chief Executive Officer, will present and company management will participate in one-on-one meetings at the Jefferies Global Healthcare Conference being held from June 5th- 6th, 2024 in New York City.